About 900 reports

  • GASTROINTESTINAL THERAPEUTICS MARKET, GLOBAL, CLINICAL TRIAL DURATION BY
  • shows that, when gastrointestinal clinical trials are segmented by molecular target,

Global Gastrointestinal Drug Market to 2022 - Pipeline Characterized by Emerging Biologic Therapies, While TNF Inhibitors and PPIs Continue to Dominate Therapy Landscape Summary Gastrointestinal disorders are common, and a number of them have a large patient population. Across the seven major markets (the US, the UK, France,...

  • Clinical Research
  • World
  • Market Size
  • AstraZeneca PLC
  • Takeda Pharmaceutical Company Limited
  • Musculoskeletal Drugs was the largest segment in the region market at 15.5% of the market worth about $6.4 billion.

Drugs For Respiratory Diseases P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A G E | ## ## P A

  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • Respiratory Monitoring
  • Market Size

ipage=##& xml=##& quest=##& rid=##& section=##& sequence=-##& pdf=##& dn=## [Accessed February ##, 2017].

  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • Pfizer Inc.
  • Roche Group

GLP-## agonists have been associated with a common side effect of gastrointestinal disturbances such as nausea and vomiting, which can reduce patient compliance (Prasad-Reddy and Isaacs, 2015).

  • Clinical Research
  • World
  • AstraZeneca PLC
  • Boehringer Ingelheim GmbH
  • Eli Lilly & Co.
  • Clinical Trials by E7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials
  • Clinical Trials by G7 Countries: Proportion of Functional (Non Ulcer) Dyspepsia to Gastrointestinal Clinical Trials

Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Functional (Non Ulcer) Dyspepsia Global Clinical Trials Review, H1, 2015" provides data on the Functional (Non Ulcer) Dyspepsia clinical trial scenario. This report provides elemental information and data...

  • Clinical Research
  • World
  • Actavis plc
  • Astellas Pharma Inc.
  • Zeria Pharmaceutical Co., Ltd.

Students are also demonstrated the examination of gastrointestinal endoscopy.

  • Healthcare
  • Managed Care
  • Medical Education
  • World
  • Market Size

Additionally, as CF is a multi-system disease pancreatic, gastrointestinal and reproductive problems will remain even if the lung transplant is successful.

  • Clinical Research
  • World
  • Market Size
  • Alexion Pharmaceuticals, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Porter's Five Forces Analysis

Phase ## and Phase ##, then phase ## WHICH ONE IS THE FASTEST GROWING?

  • Clinical Research
  • World
  • Forecast
  • Market Size
  • Supply

Minor AEs such as stomatitis, headaches, fatigue and gastrointestinal problems such as nausea and vomiting may occur when using Metolate.

  • Clinical Research
  • Dermatological Treatment
  • World
  • AbbVie Inc.
  • Allergan plc

Gastrointestinal Cancer Research; ##(##): ##-## Mayo Clinic (2014).

  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • World
  • Janssen Biotech, Inc.

As such, non-selective COX inhibitors typically produce COX-## inhibitory gastrointestinal (GI) side effects, including gastric ulceration, bleeding and perforation.

  • Clinical Research
  • World
  • Market Size
  • Allergan plc
  • Amgen Inc.
  • 8.2 ALL PIPELINE DRUGS BY PHASE

DURING CHILDHOOD, ASTHMA IS MORE COMMON IN MALES, WITH A MALE-TO-FEMALE RATIO OF ##:## UP TO PUBERTY, WHEN IT CHANGES TO ##:##.

  • Clinical Research
  • Dermatological Treatment
  • Respiratory Monitoring
  • World
  • Market Size

When gastrointestinal AEs were reported their intensity was much lower than with oxycodone.

  • Clinical Research
  • World
  • Amgen Inc.
  • Daiichi Sankyo Company
  • Eli Lilly & Co.
  • RA Therapeutics Market, Competitor Matrix for RA Marketed and Pipeline Products, 2017

Biologics are susceptible to metabolism in the gastrointestinal tract and lack permeability, which collectively leads to poor bioavailability.

  • Clinical Research
  • Dermatological Treatment
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.
  • Ph ase I
  • Pharmaceutical Industry, Clinical Trial Duration in Phase I by Therapy Area, 2006-

Health Affairs; ##(##): ##-## Vernon J, et al. (2010).

  • Clinical Research
  • Pharmaceutical
  • Therapy
  • United States
  • Market Size

Heparin is given intravenously due to poor gastrointestinal tract absorbability.

  • Clinical Research
  • Dermatological Treatment
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.

Gastrointestinal Cancer Research; ##(##): ##-## Hurwitz H, et al. (2004).

  • Cancer
  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • Merck & Co., Inc.

The ACURATE family of valve products is one of two valve systems in the Boston Scientific structural heart portfolio.

  • Clinical Research
  • Prosthesis
  • United States
  • Edwards Lifesciences Corporation
  • Valtech Cardio, Ltd.

This method avoids the gastrointestinal tract and leads to more rapid effects, compared to orally administered levodopa.

  • Clinical Research
  • World
  • Biogen Idec Inc.
  • Novartis AG
  • Roche Group

Dietary factors have a substantial influence on the risk of cancers of the gastrointestinal tract.

  • Clinical Research
  • World
  • Market Size
  • Juno Therapeutics Inc.
  • Merck & Co., Inc.

GLP-## IS AN INCRETIN HORMONE THAT IS RELEASED FROM CELLS IN THE GASTROINTESTINAL TRACT INTO THE CIRCULATION IN RESPONSE TO INGESTED NUTRIENTS FROM FOOD.

  • Clinical Research
  • Managed Care
  • Southeast Asia
  • Novo Nordisk Group
  • Sanofi S.A.

One-year treatment of obesity: a randomized, double-blind, placebocontrolled, multicenter study of orlistat, a gastrointestinal lipase inhibitor.

  • Clinical Research
  • World
  • Eli Lilly & Co.
  • Merck & Co., Inc.
  • Novo Nordisk Group
  • Uveitis Therapeutics Market, Comparative Efficacy and Safety Heatmap for Marketed Products for the Treatment of Uveitis

Indian Journal of Ophthalmology; ##(##): ## Pfizer.

  • Clinical Research
  • Dermatological Treatment
  • World
  • Forecast
  • Market Size

The Pharma Innovation; ##(##): ##-## Bresnick GH (1983).

  • Clinical Research
  • Dermatological Treatment
  • World
  • Adverum Biotechnologies, Inc.
  • Alcon, Inc.

Report Title Published Date ##.

  • Clinical Research
  • Managed Care
  • North America
  • United States
  • Horizon Discovery

IMRT HAS HELPED TO DECREASE THE OCCURRENCE OF GASTROINTESTINAL (GI) TOXICITIES USUALLY ASSOCIATED WITH EBRT.

  • Clinical Research
  • Managed Care
  • Prostate Cancer
  • Therapy
  • PROVENGE group
  • LINZESS: CURRENT STATUS OF DEVELOPMENT
  • 8.3.7. CLINICAL STUDIES

DIGESTIVE AND GASTROINTESTINAL DISORDERS DIGESTIVE AND GASTROINTESTINAL DISORDERS ARE ONE OF THERAPEUTIC AREAS THAT ARE TARGETED BY SEVERAL ORAL PEPTIDE / PROTEIN THERAPEUTICS THAT ARE EITHER MARKETED OR UNDER DEVELOPMENT.

  • Clinical Research
  • North America
  • United States
  • Ironwood Pharmaceuticals, Inc.
  • Novo Nordisk Group

Surgery; ##(##): ##-##.

  • Clinical Research
  • Dermatological Treatment
  • Managed Care
  • Novartis AG
  • Pfizer Inc.

Overall, there was one serious adverse event of moderate gastrointestinal infection that was determined by the investigator not to be drugrelated.

  • Clinical Research
  • Managed Care
  • World
  • Market Size
  • Pharming Group NV

ORAL MEDICATIONS THAT INCLUDE ANTIBIOTICS AND RETINOIDS HAVE LED TO INCREASED HEPATOTOXICITY, GASTROINTESTINAL ISSUES AND SUICIDAL TENDENCIES, ALONG WITH THE ABOVE MENTIONED ISSUES.

  • Clinical Research
  • Dermatological Treatment
  • World
  • Forecast
  • Allergan plc